236 related articles for article (PubMed ID: 26489812)
1. Thrombin time and anti-IIa dabigatran's activity: hypothesis of thrombin time's predictive value.
Le Guyader M; Kaabar M; Lemaire P; Pineau Vincent F
Ann Biol Clin (Paris); 2015; 73(5):544-6. PubMed ID: 26489812
[TBL] [Abstract][Full Text] [Related]
2. From laboratory to clinical practice: Dabigatran effects on thrombin generation and coagulation in patient samples.
Helin TA; Lemponen M; Hjemdahl P; Rönquist-Nii Y; Lassila R; Joutsi-Korhonen L
Thromb Res; 2015 Jul; 136(1):154-60. PubMed ID: 25981140
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, with coadministration of digoxin.
Stangier J; Stähle H; Rathgen K; Roth W; Reseski K; Körnicke T
J Clin Pharmacol; 2012 Feb; 52(2):243-50. PubMed ID: 21868715
[TBL] [Abstract][Full Text] [Related]
4. Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels.
Hawes EM; Deal AM; Funk-Adcock D; Gosselin R; Jeanneret C; Cook AM; Taylor JM; Whinna HC; Winkler AM; Moll S
J Thromb Haemost; 2013 Aug; 11(8):1493-502. PubMed ID: 23718677
[TBL] [Abstract][Full Text] [Related]
5. Design, Synthesis, and Biological Evaluation of Dabigatran Etexilate Mimics, a Novel Class of Thrombin Inhibitors.
Wang S; Dai P; Xu Y; Chen Q; Zhu Q; Gong G
Arch Pharm (Weinheim); 2015 Aug; 348(8):595-605. PubMed ID: 26120827
[TBL] [Abstract][Full Text] [Related]
6. Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran.
Stangier J; Feuring M
Blood Coagul Fibrinolysis; 2012 Mar; 23(2):138-43. PubMed ID: 22227958
[TBL] [Abstract][Full Text] [Related]
7. γT -S195A thrombin reduces the anticoagulant effects of dabigatran in vitro and in vivo.
Sheffield WP; Lambourne MD; Eltringham-Smith LJ; Bhakta V; Arnold DM; Crowther MA
J Thromb Haemost; 2014 Jul; 12(7):1110-5. PubMed ID: 24815541
[TBL] [Abstract][Full Text] [Related]
8. The effects of dabigatran on lupus anticoagulant, diluted plasma thrombin time, and other specialized coagulation assays.
Kim YA; Gosselin R; Van Cott EM
Int J Lab Hematol; 2015 Aug; 37(4):e81-4. PubMed ID: 25515302
[No Abstract] [Full Text] [Related]
9. The effect of dabigatran on select specialty coagulation assays.
Adcock DM; Gosselin R; Kitchen S; Dwyre DM
Am J Clin Pathol; 2013 Jan; 139(1):102-9. PubMed ID: 23270905
[TBL] [Abstract][Full Text] [Related]
10. Reversal of dabigatran anticoagulation ex vivo: Porcine study comparing prothrombin complex concentrates and idarucizumab.
Honickel M; Treutler S; van Ryn J; Tillmann S; Rossaint R; Grottke O
Thromb Haemost; 2015 Apr; 113(4):728-40. PubMed ID: 25567155
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and structural exploration of novel fluorinated dabigatran derivatives as direct thrombin inhibitors.
Li ML; Ren YJ; Dong MH; Ren WX
Eur J Med Chem; 2015; 96():122-38. PubMed ID: 25874337
[TBL] [Abstract][Full Text] [Related]
12. Diluted thrombin time reliably measures low to intermediate plasma dabigatran concentrations.
Božič-Mijovski M; Malmström RE; Malovrh P; Antovic JP; Vene N; Šinigoj P; Mavri A
Ann Clin Biochem; 2016 Jul; 53(Pt 4):446-51. PubMed ID: 26392631
[TBL] [Abstract][Full Text] [Related]
13. The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the Hemoclot thrombin inhibitor assay in patient plasma samples.
Hapgood G; Butler J; Malan E; Chunilal S; Tran H
Thromb Haemost; 2013 Aug; 110(2):308-15. PubMed ID: 23783268
[TBL] [Abstract][Full Text] [Related]
14. Prothrombin Complex Concentrate Is Effective in Treating the Anticoagulant Effects of Dabigatran in a Porcine Polytrauma Model.
Honickel M; Braunschweig T; van Ryn J; Ten Cate H; Spronk HM; Rossaint R; Grottke O
Anesthesiology; 2015 Dec; 123(6):1350-61. PubMed ID: 26414500
[TBL] [Abstract][Full Text] [Related]
15. Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity.
van Ryn J; Stangier J; Haertter S; Liesenfeld KH; Wienen W; Feuring M; Clemens A
Thromb Haemost; 2010 Jun; 103(6):1116-27. PubMed ID: 20352166
[TBL] [Abstract][Full Text] [Related]
16. Antithrombotic activity of HY023016, a novel Dabigatran prodrug evaluated in animal thrombosis models.
Li YZ; Gong GQ; Yang WH; Wang XH; Jiang ML; Zhou Y; Yang XZ; Xu YG; He GW
Thromb Res; 2013 May; 131(5):425-35. PubMed ID: 23535565
[TBL] [Abstract][Full Text] [Related]
17. Inhibitory effects of dabigatran etexilate, a direct thrombin inhibitor, on osteoclasts and osteoblasts.
Rocha AL; Bighetti-Trevisan RL; Duffles LF; de Arruda JAA; Taira TM; Assis BRD; Macari S; Diniz IMA; Beloti MM; Rosa AL; Fukada SY; Goulart GAC; Ribeiro DD; Abreu LG; Silva TA
Thromb Res; 2020 Feb; 186():45-53. PubMed ID: 31883999
[TBL] [Abstract][Full Text] [Related]
18. The effect of dabigatran on the kaolin-activated whole blood thromboelastogram.
'Aho A; Byrne K
Anaesth Intensive Care; 2016 Nov; 44(6):729-733. PubMed ID: 27832560
[TBL] [Abstract][Full Text] [Related]
19. Estimation of dabigatran plasma concentrations in the perioperative setting. An ex vivo study using dedicated coagulation assays.
Douxfils J; Lessire S; Dincq AS; Hjemdahl P; Rönquist-Nii Y; Pohanka A; Gourdin M; Chatelain B; Dogné JM; Mullier F
Thromb Haemost; 2015 Apr; 113(4):862-9. PubMed ID: 25519251
[TBL] [Abstract][Full Text] [Related]
20. In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate.
Wienen W; Stassen JM; Priepke H; Ries UJ; Hauel N
Thromb Haemost; 2007 Jul; 98(1):155-62. PubMed ID: 17598008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
